Revenue - Viatris Agreement (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share			35.00%
Upfront payment receivable			$ 205,000
Revefenacin Monotherapy (TD-4208)
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable			160,000
Revefenacin Monotherapy (TD-4208) | Success Based Development Regulatory And Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable			10,000
Revefenacin Monotherapy (TD-4208) | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable			150,000
Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable			45,000
YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable			$ 160,000
Viatris
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share			65.00%
Upfront payment receivable			$ 52,500
Viatris | Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable			$ 7,500
Viatris | YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	35.00%	35.00%	35.00%	35.00%
Upfront payment receivable			$ 45,000
Revenues	$ 20,414	$ 18,698	56,111	$ 51,158
Viatris | YUPELRI Monotherapy | Success Based Development Regulatory And Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable			7,500
Viatris | YUPELRI Monotherapy | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable			37,500
Viatris | Collaborative Arrangement | Collaboration revenue
Collaborative Arrangements and Co-Promote Agreement
Revenues	$ 15,687	$ 12,445	$ 39,841	$ 34,010